LRRC1 and neoplasm: This suggests a model in which LRRC1 activates a parallel VEGFA/VEGFR2 axis that sustains angiogenesis and tumor growth even when primary pathways—such as RAF/MEK/ERK signaling or other receptor tyrosine kinases—are inhibited by sorafenib or other drugs, ultimately leading to treatment resistance.